Back to search page


H2020-SC1-BHC-10-2019: public procurers and experts in Next Generation Sequencing, genomics, ethics and data protection are sought for routine diagnosis in haematology and oncology




A Spanish public hospital is looking for partners for submitting a proposal to the call H2020-SC1-BHC-10-2019: Innovation Procurement: Next Generation Sequencing (NGS) for routine diagnosis.
Public procurers and experts in NGS, genomics, ethics and data protection in the field of haematology and oncology are sought for developing personalised medicine solutions and scale-up demand driven innovation for healthcare systems.


Although there have been unprecedented advances over the last decade in the speed and throughput of NGS (Next Generation Sequencing) platforms, the challenge is still the application of NGS for the integrated diagnosis and treatment of hematological neoplasms. The emergence of NGS imposes increasing demands on statistical methods and bioinformatic tools for the analysis and management of these data. Not all the genes are analysed with equal precision by this technique (e.g.: insertions and long deletions do often escape from standard computer analyses; similarly, there are specific genomic regions that are difficult to capture in the sample preparation before sequencing). Therefore, the use of NGS data for integrated diagnosis is given not only by the enormous amount of data that should be manipulated at the same time, but also by the great complexity for biological interpretation.
This project aims to develop a NGS platform at an EU level for routine diagnosis and personalised medicine in haematology and oncology. This will be based on the use of NGS and the development of methods for data collection, management, and data analysis and interpretation. The platform will aid clinical decision making based on personalised medicine and fosters health research in oncology and haematology.
The project will be submitted to the call “H2020-SC1-BHC-10-2019: Innovation Procurement: Next Generation Sequencing (NGS) for routine diagnosis” (maximum budget ranges between 9 and 11 M€).
The project has duration of 192 weeks. Deadlines for the call and expressions of interest are 16th April 2019 and 30th September 2018, respectively.

Partner expertise sought:

- Specific area of activity of the partner: • Public Procurers: Health Services, Hospitals, etc. with interests in NGS in the field of hematology and oncology.
• Technical expert: Bioinformatics
• Research institute: NGS, genomics domain
• Legal advisors experts in General Data Protection Regulation (GDPL)
• Communication Office: expertise in healthcare domain
• Procurement advisor: specialists in Public Procurement of Innovation
• Ethical expert: patient rights

Advantages & innovations:

The complexity of the data generated by NGS sequencers requires highly qualified personnel for biological interpretation. Also, the scarcity of guidelines at an international level for onco-haematological diagnosis has forced researchers to struggle to interpret the results and detect recurrent errors during the sequencing process.
The project will focus on the haematology and oncology domains to tackle acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Gaining additional information about the mutational landscape of AML by NGS would increase the understanding of the mechanisms underlying AML. Although morphology is the reference strategy for MDS diagnosis, the use of NGS would provide precise information on the evolution of the tumour in each specific patient, both by the number and the type of mutations.
This project will launch a Pre-Commercial Procurement (PCP) oriented to deliver novel solutions aimed to:
• Overcome current problems in the processing of genomic information through software tools and computing capacity.
• Create a genomic cloud that offers the services of sequencing, processing, storage and reporting of the results of the tests performed.
• Provide health information systems for prevention, diagnosis and the application of effective treatments based on personalised medicine.

The main expected outcomes of this project are to:
• Facilitate improvements in the prognostic scoring systems.
• Enhance the detection of residual disease, in combination with other techniques (flow cytometry, quantitative Polymerase Chain Reactions methods, etc).
• Develop a broad number of genetic tests aimed to identify the molecular targets and improve the targeted therapies.

Development Stage:

Proposal under development - The proposal is currently under development.


Copyright - -

Programme - Call:

Evaluation scheme: Single stage


Deadline: 16/04/2019

Coordinator required: No

or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here


Country of origin
Profile date


Research cooperation agreement


Life Sciences \ Biosciences and Health \ Environment & Protecting Man \ Drug Discovery and Drug Development \ Diagnostics \ Medical Devices
BIOLOGICAL SCIENCES / Medicine, Human Health / Medical Research / BIOLOGICAL SCIENCES / Genome Research / Bioinformatics / BIOLOGICAL SCIENCES / Genome Research / Gene Expression, Proteome Research / BIOLOGICAL SCIENCES / Genome Research / Population genetics / BIOLOGICAL SCIENCES / E-Health / Health information management
Hospital activities
COMPUTER RELATED / Computer Software / Medical/health software / GENETIC ENGINEERING/MOLECULAR BIOLOGY / Population genetics


Contact Enterprise Europe Network Scotland by email at, quoting reference number RDES20180510001